Our Pipeline

Clinical Studies

We are currently conducting six international clinical research studies; two Phase 3 studies with linzagolix in women with heavy menstrual bleeding associated with uterine fibroids (PRIMROSE 1 & 2),  two Phase 3 studies with linzagolix in women with endometriosis-associated pain (EDELWEISS 2 & 3), one Phase 3 study with nolasiban in women undergoing IVF (IMPLANT 4) and one clinical Phase 2a study with Ebopiprant (OBE022) in preterm labour (PROLONG).

Primrose 1 & 2: Heavy Menstrual Bleeding due to Uterine Fibroids

Primrose 1 & 2 are clinical research studies evaluating linzagolix in women with heavy menstrual bleeding due to uterine fibroids. Each study is treating women with either 100 mg, 200 mg of linzagolix once daily with or without add-back therapy or placebo for 24 to 52 weeks.

Status: recruitment completed

Edelweiss 2 & 3: Endometriosis Associated Pain

Edelweiss 2 & 3 are clinical research studies evaluating linzagolix in women with endometriosis associated pain. Each study is treating women with either 75 mg of linzagolix, 200 mg of linzagolix with add-back therapy or placebo once daily for 24 weeks.

Status: recruiting Website

Implant 4: Nolasiban in IVF

IMPLANT 4 is a clinical research study evaluating nolasiban in women undergoing IVF. Women receive a single administration of 900 mg of nolasiban or placebo prior to undergoing embryo transfer.

Status: recruitment completed

Prolong: Preterm labour

PROLONG is a clinical research study evaluating Ebopiprant (OBE022) in pregnant women with threatened spontaneous preterm labour.

Status: recruiting

What is a Clinical Research study?

A Clinical research study (also called a clinical trial) is a medical study conducted with patient volunteers, that helps to answer important questions about an investigational medication, such as: does it work? All medications must be tested in Clinical research studies before they can be approved to be prescribed to patients. Without people taking part in these studies, we would have no new medications.

 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue